Hemostemix Inc. (CVE:HEM – Get Free Report) shares passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$0.06 and traded as high as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 5,001 shares traded.
Hemostemix Trading Up 7.1%
The company has a market capitalization of C$15.86 million, a PE ratio of -3.75 and a beta of 0.22. The company has a debt-to-equity ratio of -61.85, a current ratio of 0.13 and a quick ratio of 0.48. The company’s fifty day moving average is C$0.07 and its 200-day moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
